Cargando…
Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073355/ https://www.ncbi.nlm.nih.gov/pubmed/37014455 http://dx.doi.org/10.1186/s13550-023-00976-5 |
_version_ | 1785019550323965952 |
---|---|
author | Jiang, Maoqing Chen, Ping Guo, Xiuyu Zhang, Xiaohui Gao, Qiaoling Zhang, Jingfeng Zhao, Guofang Zheng, Jianjun |
author_facet | Jiang, Maoqing Chen, Ping Guo, Xiuyu Zhang, Xiaohui Gao, Qiaoling Zhang, Jingfeng Zhao, Guofang Zheng, Jianjun |
author_sort | Jiang, Maoqing |
collection | PubMed |
description | BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deoxy-2-deoxyglucose ((18)F-FDG) PET/CT and serum tumor markers (STMs) to determine EGFR mutation status in male patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent (18)F-FDG PET/CT scan before treatment and monitored 8 STMs (cytokeratin 19 fragment [CYFRA21-1], squamous cell carcinoma-related antigen [SCC-Ag], carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], carbohydrate antigen [CA] 50, CA125, CA72-4, and ferritin). A comparison was done between EGFR mutant and wild-type patients in terms of the maximum standardized uptake value of primary tumors (pSUV(max)) and 8 STMs. We performed receiver operating characteristic (ROC) curve and multiple logistic regression analyses to determine predictors for EGFR mutation status. RESULTS: EGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUV(max) (< 8.75), low serum SCC-Ag (< 0.79 ng/mL) and CYFRA21-1 (< 2.91 ng/mL) concentrations. The area under ROC curve values were 0.679, 0.655, 0.685 and 0.754, respectively, for low CYFRA21-1, SCC-Ag, pSUV(max) and the combination of these three factors. CONCLUSIONS: We demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUV(max), were associated with EGFR mutations, and that the combination of these factors resulted in a higher differentiation of EGFR mutation status in male patients with NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-00976-5. |
format | Online Article Text |
id | pubmed-10073355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-100733552023-04-06 Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag Jiang, Maoqing Chen, Ping Guo, Xiuyu Zhang, Xiaohui Gao, Qiaoling Zhang, Jingfeng Zhao, Guofang Zheng, Jianjun EJNMMI Res Original Research BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deoxy-2-deoxyglucose ((18)F-FDG) PET/CT and serum tumor markers (STMs) to determine EGFR mutation status in male patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent (18)F-FDG PET/CT scan before treatment and monitored 8 STMs (cytokeratin 19 fragment [CYFRA21-1], squamous cell carcinoma-related antigen [SCC-Ag], carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], carbohydrate antigen [CA] 50, CA125, CA72-4, and ferritin). A comparison was done between EGFR mutant and wild-type patients in terms of the maximum standardized uptake value of primary tumors (pSUV(max)) and 8 STMs. We performed receiver operating characteristic (ROC) curve and multiple logistic regression analyses to determine predictors for EGFR mutation status. RESULTS: EGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUV(max) (< 8.75), low serum SCC-Ag (< 0.79 ng/mL) and CYFRA21-1 (< 2.91 ng/mL) concentrations. The area under ROC curve values were 0.679, 0.655, 0.685 and 0.754, respectively, for low CYFRA21-1, SCC-Ag, pSUV(max) and the combination of these three factors. CONCLUSIONS: We demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUV(max), were associated with EGFR mutations, and that the combination of these factors resulted in a higher differentiation of EGFR mutation status in male patients with NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-00976-5. Springer Berlin Heidelberg 2023-04-04 /pmc/articles/PMC10073355/ /pubmed/37014455 http://dx.doi.org/10.1186/s13550-023-00976-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Jiang, Maoqing Chen, Ping Guo, Xiuyu Zhang, Xiaohui Gao, Qiaoling Zhang, Jingfeng Zhao, Guofang Zheng, Jianjun Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title | Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title_full | Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title_fullStr | Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title_full_unstemmed | Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title_short | Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag |
title_sort | identification of egfr mutation status in male patients with non-small-cell lung cancer: role of (18)f-fdg pet/ct and serum tumor markers cyfra21-1 and scc-ag |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073355/ https://www.ncbi.nlm.nih.gov/pubmed/37014455 http://dx.doi.org/10.1186/s13550-023-00976-5 |
work_keys_str_mv | AT jiangmaoqing identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT chenping identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT guoxiuyu identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT zhangxiaohui identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT gaoqiaoling identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT zhangjingfeng identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT zhaoguofang identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag AT zhengjianjun identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag |